Advertisement
Table 1 Breast cancer and prostate cancer repositioned drug candidates identified from analysis of LINCS. Complete lists of repositioned drug candidates for breast cancer and prostate cancer are shown in Additional file 13
| Breast Cancer | Prostate Cancer | |||
|---|---|---|---|---|
| Total compounds | 3678 | 4228 | ||
| Compounds that are FDA drugs | 632 | 676 | ||
| Compounds that are FDA drugs for target disease | 20 | 11 | ||
| Compounds that are in clinical trial for target disease | 154 | 106 | ||
| UCDB | DCUB | UCDB | DCUB | |
| Compounds with FDR < 0.05 | 2435 | 1875 | 2500 | 1668 |
| Compounds that are clinical drugs with FDR < 0.05 (p-value) | 131 (6.2E-8) | 109 (2.7E-7) | 82 (4.9E-5) | 67 (4.8E-7) |
| FDA drugs with FDR < 0.05 | 427 | 325 | 456 | 317 |
| FDA drugs with FDR < 0.05 in both UCDB and DCUB | 244 | 291 | ||
| FDA drugs for target disease with FDR < 0.05 (p-value) | 20 (2.5E-4) | 19 (2.7E-5) | 10 (2.6E-2) | 9 (5.3E-3) |
| AUC (p-value) | 0.86 (<1.0E-6) | 0.81 (<1.0E-6) | 0.77 (9E-3) | 0.83 (4.7E-5) |
| Number of MAG/DRG | 237/700 | 75/100 | 333/100 | 46/100 |
